Infection, recovery and re-infection of farmed mink with SARS-CoV-2.
Animals
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
COVID-19
/ veterinary
COVID-19 Nucleic Acid Testing
COVID-19 Serological Testing
Farms
Follow-Up Studies
Humans
Mink
/ immunology
Mutation
Pharynx
/ virology
Phylogeny
RNA, Viral
Reinfection
/ virology
SARS-CoV-2
/ genetics
Spike Glycoprotein, Coronavirus
/ genetics
Whole Genome Sequencing
Journal
PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
11
08
2021
accepted:
27
10
2021
revised:
29
11
2021
pubmed:
16
11
2021
medline:
15
12
2021
entrez:
15
11
2021
Statut:
epublish
Résumé
Mink, on a farm with about 15,000 animals, became infected with SARS-CoV-2. Over 75% of tested animals were positive for SARS-CoV-2 RNA in throat swabs and 100% of tested animals were seropositive. The virus responsible had a deletion of nucleotides encoding residues H69 and V70 within the spike protein gene as well as the A22920T mutation, resulting in the Y453F substitution within this protein, seen previously in mink. The infected mink recovered and after free-testing of 300 mink (a level giving 93% confidence of detecting a 1% prevalence), the animals remained seropositive. During further follow-up studies, after a period of more than 2 months without any virus detection, over 75% of tested animals again scored positive for SARS-CoV-2 RNA. Whole genome sequencing showed that the viruses circulating during this re-infection were most closely related to those identified in the first outbreak on this farm but additional sequence changes had occurred. Animals had much higher levels of anti-SARS-CoV-2 antibodies in serum samples after the second round of infection than at free-testing or during recovery from initial infection, consistent with a boosted immune response. Thus, it was concluded that following recovery from an initial infection, seropositive mink were readily re-infected by SARS-CoV-2.
Identifiants
pubmed: 34780574
doi: 10.1371/journal.ppat.1010068
pii: PPATHOGENS-D-21-01633
pmc: PMC8629378
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
RNA, Viral
0
Spike Glycoprotein, Coronavirus
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1010068Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist
Références
Mol Biol Evol. 2018 Jun 1;35(6):1547-1549
pubmed: 29722887
Science. 2020 Aug 14;369(6505):818-823
pubmed: 32616673
Science. 2021 Jan 8;371(6525):172-177
pubmed: 33172935
Lancet Infect Dis. 2020 Sep;20(9):1051-1060
pubmed: 32539986
NPJ Vaccines. 2021 May 10;6(1):67
pubmed: 33972565
Nat Commun. 2020 Jul 6;11(1):3436
pubmed: 32632160
Lancet Microbe. 2020 Sep;1(5):e218-e225
pubmed: 32838346
Euro Surveill. 2021 Feb;26(5):
pubmed: 33541485
mSphere. 2020 Jun 24;5(3):
pubmed: 32581081
Nat Commun. 2020 Nov 25;11(1):5986
pubmed: 33239633
Science. 2020 May 29;368(6494):1016-1020
pubmed: 32269068
Sci Immunol. 2020 Dec 22;5(54):
pubmed: 33443036
Occup Environ Med. 2021 Dec;78(12):893-899
pubmed: 34330815
Mol Biol Evol. 2013 Apr;30(4):772-80
pubmed: 23329690
Euro Surveill. 2021 Jan;26(3):
pubmed: 33478625
Euro Surveill. 2020 Jun;25(23):
pubmed: 32553059
Animals (Basel). 2021 Jan 12;11(1):
pubmed: 33445704
Cell Rep. 2021 Jun 29;35(13):109292
pubmed: 34166617
Emerg Infect Dis. 2021 Feb;27(2):547-551
pubmed: 33207152
Lancet. 2021 Mar 27;397(10280):1204-1212
pubmed: 33743221
Front Microbiol. 2021 Jun 25;12:698944
pubmed: 34248922
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Natl Sci Rev. 2020 Dec 08;8(3):nwaa291
pubmed: 34676095
Sci Adv. 2020 Jun 17;6(25):eabb5813
pubmed: 32596474
J Infect. 2021 Mar;82(3):399-406
pubmed: 33589297
Emerg Infect Dis. 2021 Mar;27(3):928-931
pubmed: 33350923